Geode Capital Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-152,332
| Closed | -$89.9K | – | 4521 |
|
|
2024
Q4 | $89.9K | Hold |
152,332
| – | – | ﹤0.01% | 4121 |
|
|
2024
Q3 | $120K | Sell |
152,332
-23,086
| -13% | -$23.1K | ﹤0.01% | 4052 |
|
|
2024
Q2 | $223K | Buy |
175,418
+15,669
| +10% | +$20.7K | ﹤0.01% | 3871 |
|
|
2024
Q1 | $222K | Buy |
159,749
+7,672
| +5% | +$12.7K | ﹤0.01% | 3904 |
|
|
2023
Q4 | $242K | Buy |
152,077
+51,570
| +51% | +$65.7K | ﹤0.01% | 3869 |
|
|
2023
Q3 | $143K | Buy |
100,507
+119
| +0.1% | +$183 | ﹤0.01% | 4120 |
|
|
2023
Q2 | $160K | Buy |
100,388
+48,135
| +92% | +$61.4K | ﹤0.01% | 4142 |
|
|
2023
Q1 | $43.9K | Hold |
52,253
| – | – | ﹤0.01% | 4550 |
|
|
2022
Q4 | $74K | Buy |
52,253
+3,937
| +8% | +$6.51K | ﹤0.01% | 4494 |
|
|
2022
Q3 | $93K | Hold |
48,316
| – | – | ﹤0.01% | 4603 |
|
|
2022
Q2 | $96K | Hold |
48,316
| – | – | ﹤0.01% | 4611 |
|
|
2022
Q1 | $153K | Buy |
48,316
+1,468
| +3% | +$5.13K | ﹤0.01% | 4498 |
|
|
2021
Q4 | $174K | Sell |
46,848
-4,606
| -9% | -$26.1K | ﹤0.01% | 4541 |
|
|
2021
Q3 | $347K | Buy |
51,454
+8,877
| +21% | +$69.4K | ﹤0.01% | 4195 |
|
|
2021
Q2 | $435K | Buy |
42,577
+24,320
| +133% | +$204K | ﹤0.01% | 4005 |
|
|
2021
Q1 | $149K | Buy |
+18,257
| New | +$152K | ﹤0.01% | 4205 |
|
Geode Capital Management's CYTH Position: Q1 2025 in Review
Geode Capital Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 152,332 shares — an estimated $89.9K sold.
Geode Capital Management first reported a position in CYTH in Q1 2021 and held it in 16 quarters. The position peaked at $435K in Q2 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- Geode Capital Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Geode Capital Management sold 152,332 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $89.9K.
- Geode Capital Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
- Geode Capital Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $435K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.